A randomised, double-blind, parallel-group, 26 week study comparing the efficacy and safety of indacaterol (Onbrez Breezhaler 150µg o.d.) with salmeterol/fluticasone propionate (Seretide Accuhaler 50 µg/500 µg b.i.d.) in patients with moderate obstructive pulmonary disease

Trial Profile

A randomised, double-blind, parallel-group, 26 week study comparing the efficacy and safety of indacaterol (Onbrez Breezhaler 150µg o.d.) with salmeterol/fluticasone propionate (Seretide Accuhaler 50 µg/500 µg b.i.d.) in patients with moderate obstructive pulmonary disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 16 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 02 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top